High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in https://pbs.twimg.com/profile_images/1800478984926334976/yyyPLP4A_normal.jpg john+RNV2@john… […]
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Ad https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john…
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE tammytilley@gm… Sun, 10/26/2025 – 19:09 Lupus Novel Rx Steroids Dr. Sheila
ACR25 Best Abstracts – Day 1 jjcush@gmail.com Sun, 10/26/2025 – 19:00
Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel bette
Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ? https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg john+RNV2@john… Sun, 10/26/2025
What are the RFs for progression of Pso to PsA? 🔸PsO disease severity – 3.2x risk —>PsA 🔸Phenotype – nail
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWAC https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun, 10/26/2025
We’ll explore how SPY072’s differentiated dosing profile could influence Spyre Therapeutics’ place in the competitive rheumatology pipeline. Rare …
ACR2025 Day 1 RECAP https://t.co/zARgu7vx3m https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Sun, 10/26/2025 – 18:01 RheumNow Dr. John Cush ACR2025 Day 1 RECAP https://t.co/zARgu7vx3m
CHICAGO — CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory systemic
… study because diagnostic reasoning in rheumatology is particularly complex due to the multisystem nature of rheumatic diseases and their
(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective
Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun,
STOP RA Cellular & Serologic Predictors tammytilley@gm… Sun, 10/26/2025 – 16:49 Rheumatoid Arthritis Labs/Biomarkers Dr. Jack Cush discusses abstract 0774,
… rheumatology therapies. The new guidelines include three strong recommendations: Taper prednisone dose to <5 mg daily within six months,;
CHICAGO — Large language models, when used alongside human clinical judgement, “substantially” improved diagnostic accuracy among a cohort of medical
Patients prescribed opioids to relieve pain associated with rheumatic disease may not always experience a benefit as it has been
New Gout Therapies Show Promise in Phase III Trials tammytilley@gm… Sun, 10/26/2025 – 16:06
Upadacitinib in GCA doesn’t just affect IL-6, it alters IFNg, known to be important in vascular change in GCA. If
A closer look in skin toxicity of GCs in RMDs GC Toxicity Index, LONG TOX prospective cohort Frequent: -Easy bruising
Nice SRMA evaluating HCQ dosing >5mg/kg associated w/3.8x risk of retinopathy… …but <5mg/kg associated w/1.8 https://pbs.twimg.com/profile_images/1982460526815764480/EQEuBdmh_normal.jpg john+RNV2@john… Sun, 10/26/2025 –
PD-1+ effector memory T cells in PsA synovium are functionally active and regulate Th17 cytokines via STAT3/RORγt. Reco https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john…
What is #nonadherence in #SLE associated with? 115 Pts w #lupus in Spain Overall medication adherence 58%! 👇Reduce https://pbs.twimg.com/profile_images/1007774150000332801/SjLeJk3G_normal.jpg john+RNV2@john…
Two Jacks, One mission 🤓 Head on to the booth and get a chance to meet either one of them
CE study BEL vs csDMARDs in TriNetX Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analys
#ACR25 Abstr#802 In #SLE pts with CLASI-A ≥8, pooled post-hoc analysis of Phase 2 RCT showed enpatoran, oral small mol
